Skip to main content

Table 3 Dose schedules and dose-limiting toxicities of MK-2206 in combination therapy

From: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Treatment arm MK-2206 dosing schedule Evaluable patients Dose-limiting toxicities
1 Carboplatin AUC 6 45 mg QODb 5 1; rash
  60 mg QODb 4 3a; rash, febrile neutropenia (2)
  90 mg Q3W 5 1; rash
Paclitaxel 200 mg/m2    
  135 mg Q3W 5 1; TCP
  200 mg Q3W 5 2; rash
2 Docetaxel 75 mg/m2 45 mg QODb 5 3; febrile neutropenia
Docetaxel 60 mg/m2 90 mg Q3W 3 0
  135 mg Q3W 3 0
  200 mg Q3W 4 1; tinnitus
3 Erlotinib 100 mg 45 mg QODc 8 2; rash, stomatitis
  135 mg QW 4 0
Erlotinib 150 mg 45 mg QODc 3 1; rash
   135 mg QW 5 1; rash
  1. Abbreviation: TCP thrombocytopenia.
  2. a3 events in 2 patients.
  3. bdays 1–7.
  4. ccontinuous.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us